Deficient mitophagy contributes to Parkinson's disease and aging itself.
Vincere's small molecules increase mitophagy and have potential to be the first ever medicines to slow or stop Parkinson's disease and other age-related diseases.
To develop these small molecules we have raised equity and grant funding, including research support from expert agencies such as the Michael J. Fox Foundation and NIH.
We have recruited top talent to plan and execute on these projects within an aggressive timeline.
Vincere is a resident of Johnson & Johnson Innovation - JLABS and recipient of a golden ticket award from Bristol Myers Squibb.